GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation

03.06.25 14:00 Uhr

Recognizing exceptional leadership in patient education and clinical skill in the GammaTile procedure 

TEMPE, Ariz., June 3, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company focused on improving the lives of patients with brain tumors, today announced Westchester Medical Center as the latest GammaTile® Center of Excellence Program designation.

(PRNewsfoto/GT Medical Technologies)

The program recognizes leaders in patient care dedicated to advancing brain tumor treatment. Physicians and their institutions who receive this designation have demonstrated an exceptional level of expertise in the GammaTile procedure by meeting specific clinical criteria, annual case minimums, and ongoing education requirements.

The following physicians are now recognized with achievement:

  • Simon Hanft, MD, Neurosurgeon, Section Chief, Neurosurgical Oncology
  • Rohil Shekher, MD, Radiation Oncologist, CNS Program Lead

"Receiving recognition as a GammaTile Center of Excellence is a meaningful acknowledgment of our team's dedication to advancing brain tumor treatment," said Dr. Simon Hanft, Section Chief of Neurosurgical Oncology at Westchester Medical Center. "We're proud to offer innovative options like GammaTile, which provide targeted radiation therapy precisely where it's needed while minimizing exposure to healthy brain tissue. Being able to bring this kind of hope to patients and their families is truly rewarding."

GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are at their lowest levels. Unlike conventional approaches, which often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.1

About GT Medical Technologies, Inc.
GT Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care.

About GammaTile
GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are at their lowest levels to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue.

Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit gammatile.com and follow @GammaTile on FacebookInstagramLinkedIn and X

Media Contact
Dawn Fallon
New Dawn Communications LLC
Dfallon@newdawncomms.com
732-771-7808

References

  • Garcia MA et al. J Neurooncol. 166:203-212 (2024).
  • GammaTile COE (PRNewsfoto/GT Medical Technologies)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gt-medical-technologies-welcomes-new-gammatile-center-of-excellence-program-designation-302471303.html

    SOURCE GT Medical Technologies